根据阿片类受体多形态的可变性,与劳动有关的疼痛管理
G V Tănase1,2, A E Tănase3, M Ciocoiu2
1Anesthesiology and Intensive Care Unit, "Grigore T Popa" University of Medicine and Pharmacy, Iasi, Romania.
概括
遗传变异影响疼痛感知和阿片类药物反应,影响怀孕,分娩和产后恢复期间的疼痛管理. 了解这些遗传多态化可以导致更安全,个性化的疼痛缓解策略.
科学领域:
- 药物基因组学 药物基因组学
- 疼痛管理 疼痛管理
- 产科和妇科 产科和妇科
背景情况:
- 疼痛感知和阿片类药物反应的个体间变异性受到遗传多态度的显著影响.
- 在怀孕,分娩,分娩和产后期间有效和安全地管理疼痛是一个关键的临床挑战.
- 特定的基因变异 (例如,OPRM1,CYP2D6,COMT,UGT2B7,ABCB1) 影响阿片类药物的疗效,剂量和产科患者的不良事件.
研究的目的:
- 审查当前关于疼痛相关遗传多态化在围产和妇科手术环境中的影响的证据.
- 要突出与阿片类药物代谢的遗传变异相关的风险,例如药物不足或过量服用.
- 评估药物基因组洞察力开发个性化止痛策略的潜力.
主要方法:
- 对有关遗传多态化和疼痛管理的现有文献进行系统审查.
- 对专注于分娩,剖腹产,产后康复和科妇科手术的研究进行分析.
- 关于基因药物相互作用及其临床影响的综合数据.
主要成果:
- 关键基因中的遗传多态性显著改变了阿片类药物药理动力学和药理动力学.
- 像CYP2D6这样的基因变异可以导致超快或差代谢器表型,增加疼痛控制不足或药物不良反应的风险.
- 有证据表明,在产科和妇科背景下,特定的多形态和对止痛药的可变反应之间存在强烈的联系.
结论:
- 药物遗传学知识对于优化妇产科疼痛管理至关重要.
- 基于遗传特征的个性化止痛策略可以提高治疗疗效和患者安全.
- 需要进一步的研究,才能将药物基因组学完全整合到常规临床实践中,以改善围产和手术疼痛护理.
相关概念视频
Analgesia and Pain Management
2.6K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.6K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.3K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.3K
Opioid Receptors: Overview
5.7K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
5.7K
Opioid Analgesics: Morphine and Other Natural Cogeners
1.3K
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
1.3K
Local Anesthetics: Differential Sensitivity of Nerve Fibers
1.6K
Local anesthetics (LAs) block the sodium channels of nerve trunks, sensory nerve endings, and neuromuscular junctions. Although LAs can block all kinds of nerves, the sensitivity of nerve fibers differs according to nerve types and structures. LAs are known to block myelinated fibers faster than unmyelinated ones. Also, they block pain or sensory neurons at low concentrations without affecting the motor neurons involved in muscle contractions. This helps relieve labor pain without affecting the...
1.6K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
80
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
80


